Vitro Diagnostics Inc (fka VODG)

[Potse]

MSC-Gro customer order.....

Golden, Colorado—April 29, 2015 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced expansion of manufacturing capacity based on a recent orders for bulk quantities of its MSC-Gro™ Brand of stem cell growth media. Increased demand comes from sales to stem cell researchers and a new customer who recently qualified our media for use in its clinical testing program. We have received our initial bulk order based on extensive evaluation of Vitro Biopharma’s clinical grade MSC-Gro™.

http://vitrobiopharma.com/vitro-biopharma-expands-capacity-meet-increased-demand-msc-gro-stem-cell-culture-media/

I assume the new customer referenced in the recent press release is the Australia-based company that Pete Shuster was mentioning in his January LinkedIn postings. This appears to be the positive result of 2+ years of very extensive evaluation/testing of MSC-Gro on the part of the foreign company/clinics/organizations involved.

These are statements Pete Shuster made on LinkedIn forums back in May 2013.....

1) Optimizing Expansion of Autologously Derived hMSCs

We are working with several non US orgs that are expanding fat derived Stem Cells for treatment of Musculoskeletal Disorders. The theory is better media=more hMSCs; more MSCs=better therapeutic outcomes.

2) Clinics in countries (like Australia) that have a regulatory climate that allow expansion of autologous or allogeneic MSCs for therapies have found our media to lower costs=more cells in less time:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=88341214

These are the statements Shuster made in January 2015 regarding the foreign company interested in MSC-Gro......

1) For example, Neuromics and Vitro Biopharma are working with a large processor, outside the US, to optimize their purifying and expanding of ADMSCs. They serve a growing population of Stem Cell Transplant clinics. Each lot of expanded cells are tested to make sure they comply with published International Standards. These standards include expression of expanded cells for CD Markers 90,73 and 105 be >90%.

2) We are being engaged with a company that is already expanding ADMCS with FBS/a-MEM. They are piloting our defined MSCGro media: (www.neuromics.com/ittrium/visit/A1x66x1y1x85b1x1x9cy1x622ex1x96y1xa711x1x82) to see if it would be better and more cost effective. The company is in Melbourne, Australia and they are highly regulated.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110203743

This is Shuster's LinkedIn post on the day VODG issued the press release....

MSCGro Expanding Cells for Human Transplants

This is big news for Neuromics. Though it is sadly ironic is the cell processor is not in the U.S.:

https://www.linkedin.com/grp/post/4117443-5999259380351057921